Skip to content

Author

J. Lantero-Rodríguez

We have 2 of 67 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

CSF p-tau205: a biomarker of Alzheimer's disease progression and biological staging.

CSF p-tau205 as a biomarker of Alzheimer's disease pathology and progression with potential value for biological staging is supported and when incorporated into a conceptual CSF-based staging model, the final p-tau205-positive stage showed the strongest association with cortical atrophy, cognitive impairment, and risk of progression to dementia.

J. Lantero-Rodríguez, S. Janelidze, S. Palmqvist et al. · 0 citations
Open access Jul 2026

CSF and plasma tau biomarkers in the Down syndrome–Alzheimer’s disease continuum

These findings highlight the complementary roles of CSF and plasma tau biomarkers in tracking disease progression: CSF biomarkers capture early pathological changes, whereas plasma biomarkers more effectively reflect disease progression within symptomatic stages.

J. Arranz, J. Lantero-Rodríguez, Luisa Sophie Braun-Wohlfahrt et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.